Abstract

BackgroundBenralizumab is effective in the treatment of eosinophilic asthma and is being investigated for the treatment of other eosinophil-associated diseases. Reports on the use of benralizumab for the treatment of...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Behandlung der eosinophilen Granulomatose mit Polyangiitis: Ist Benralizumab eine Alternative?
Panagiota Xanthouli
Kompass Autoimmun | VOL. 6
Panagiota XanthouliPanagiota Xanthouli
01 Jan 2024
AB0640 PREVALENCE AND DETERMINANT FACTORS OF ENDOTHELIAL DYSFUNCTION IN ANCA ASSOCIATED VASCULITIS
F Melpignano ... M A D’Agostino
-
F Melpignano, et. al.F Melpignano ... M A D’Agostino
23 May 2022
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study
Gianluca Moroncini ... Claudia Crimi
The Lancet Rheumatology | VOL. 5
Gianluca Moroncini, et. al.Gianluca Moroncini ... Claudia Crimi
06 Nov 2023
Ear, nose and throat manifestations of Churg-Strauss syndrome
Chiara Grasselli ... Nicoletta Ronda
Acta Oto-Laryngologica | VOL. 126
Chiara Grasselli, et. al.Chiara Grasselli ... Nicoletta Ronda
01 Jan 2006
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers